TrialSignal
Clinical trial intelligence report
A Randomized, Double-blind, Parallel Controlled, Phase I Study, Comparing the PK, PD, Safety, and Immunogenicity of Post-change CMAB807and Prolia in Healthy Chinese Subjects
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT06361355
Status
COMPLETED
Phase
PHASE1
Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Executive brief
Investment-Ready Snapshot
This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807 administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site, versus Prolia #Denosumab# in healthy male subjects after a single dose
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06361355
Indication
Healthy Volunteers
Modality
monoclonal antibody
Target
Post-change CMAB807, Prolia
Intervention
Post-change CMAB807, Prolia
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.